losartan has been researched along with Death, Sudden, Cardiac in 16 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Death, Sudden, Cardiac: Unexpected rapid natural death due to cardiovascular collapse within one hour of initial symptoms. It is usually caused by the worsening of existing heart diseases. The sudden onset of symptoms, such as CHEST PAIN and CARDIAC ARRHYTHMIAS, particularly VENTRICULAR TACHYCARDIA, can lead to the loss of consciousness and cardiac arrest followed by biological death. (from Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 7th ed., 2005)
Excerpt | Relevance | Reference |
---|---|---|
" We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure." | 9.11 | QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004) |
"Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan." | 9.09 | Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999) |
"The relationship of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ventricular hypertrophy with no history of AF, in sinus rhythm on their baseline electrocardiogram, randomly assigned to losartan- or atenolol-based treatment." | 5.17 | Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy. ( Bang, CN; Dahlöf, B; Devereux, RB; Hille, DA; Kjeldsen, SE; Okin, PM; Wachtell, K, 2013) |
"The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study included 9193 patients 55 to 80 years of age with essential hypertension and ECG LV hypertrophy by gender-adjusted Cornell product (CP) (RaVL+SV(3) [+6 mm in women])." | 5.12 | Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. ( Dahlöf, B; Devereux, RB; Ibsen, H; Kjeldsen, SE; Lindholm, LH; Nieminen, MS; Okin, PM; Olsen, MH; Thygesen, K; Wachtell, K, 2007) |
" We measured the QRS duration and QT intervals from the baseline 12-lead electrocardiograms in the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, which included hypertensive patients with electrocardiographic evidence of left ventricular hypertrophy randomized to either losartan-based or atenolol-based treatment to lower blood pressure." | 5.11 | QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study. ( Dahlöf, B; Devereux, RB; Jern, S; Nieminen, MS; Oikarinen, L; Okin, PM; Toivonen, L; Viitasalo, M, 2004) |
"The OPTIMAAL trial randomized 5477 patients with heart failure or evidence of left ventricular dysfunction following acute MI to losartan or captopril." | 5.11 | Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction. ( Cleland, JG; Dickstein, K; Kjekshus, J; Orn, S; Romo, M, 2005) |
"Differences in QT dispersion (a predictor for sudden death) were observed in a subgroup of patients in the ELITE heart failure study of losartan compared with captopril, and may explain improved survival with losartan." | 5.09 | Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group. ( Brooksby, P; Cowley, AJ; Klinger, G; Pitt, B; Robinson, PJ; Segal, R, 1999) |
"Rats harboring the human renin and angiotensinogen genes (dTGR) feature angiotensin (ANG) II/hypertension-induced cardiac damage and die suddenly between wk 7 and 8." | 3.74 | Angiotensin II-induced sudden arrhythmic death and electrical remodeling. ( Dechend, R; Dietz, R; Fiebeler, A; Fischer, R; Gapelyuk, A; Gratze, P; Gruner, A; Gruner, K; Luft, FC; Muller, DN; Qadri, F; Schirdewan, A; Shagdarsuren, E; Wellner, M, 2007) |
"In the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, a major reduction of all-cause mortality--especially cardiovascular mortality--in patients with diabetes with left ventricular hypertrophy was reported for treatment with losartan." | 3.72 | Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. ( Borch-Johnsen, K; Dahlöf, B; Edelman, JM; Ibsen, H; Lindholm, LH; Olsen, MH; Snapinn, S; Wachtell, K, 2003) |
"Hypertension is a major influence on the development of LVH." | 2.43 | Ventricular hypertrophy and hypertension: prognostic elements and implications for management. ( Devereux, RB; Krauser, DG, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (25.00) | 18.2507 |
2000's | 11 (68.75) | 29.6817 |
2010's | 1 (6.25) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Okin, PM | 4 |
Bang, CN | 1 |
Wachtell, K | 3 |
Hille, DA | 1 |
Kjeldsen, SE | 3 |
Dahlöf, B | 5 |
Devereux, RB | 5 |
Morin, DP | 1 |
Oikarinen, L | 2 |
Viitasalo, M | 2 |
Toivonen, L | 2 |
Nieminen, MS | 3 |
John, M | 1 |
Aronow, WS | 1 |
Lindholm, LH | 2 |
Edelman, JM | 1 |
Ibsen, H | 2 |
Borch-Johnsen, K | 1 |
Olsen, MH | 2 |
Snapinn, S | 1 |
Ong, HT | 1 |
Chong, AY | 1 |
Lip, GY | 1 |
Jern, S | 1 |
Orn, S | 1 |
Cleland, JG | 1 |
Romo, M | 1 |
Kjekshus, J | 1 |
Dickstein, K | 1 |
Krauser, DG | 1 |
Fischer, R | 1 |
Dechend, R | 1 |
Gapelyuk, A | 1 |
Shagdarsuren, E | 1 |
Gruner, K | 1 |
Gruner, A | 1 |
Gratze, P | 1 |
Qadri, F | 1 |
Wellner, M | 1 |
Fiebeler, A | 1 |
Dietz, R | 1 |
Luft, FC | 1 |
Muller, DN | 1 |
Schirdewan, A | 1 |
Thygesen, K | 1 |
Rump, LC | 1 |
Oberhauser, V | 1 |
Schwertfeger, E | 1 |
Schollmeyer, P | 1 |
Brooksby, P | 1 |
Robinson, PJ | 1 |
Segal, R | 1 |
Klinger, G | 1 |
Pitt, B | 1 |
Cowley, AJ | 1 |
Riegger, GA | 1 |
Topol, E | 1 |
Gavras, I | 1 |
Gavras, H | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
Assessment of Prolonged Paced QRS Duration as a Marker of Sudden Cardiac Death in Subjects With Implantable Cardioverter-defibrillators[NCT01948206] | 100 participants (Actual) | Observational | 2013-10-31 | Terminated (stopped due to Ran out of funds) | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 reviews available for losartan and Death, Sudden, Cardiac
Article | Year |
---|---|
Ventricular hypertrophy and hypertension: prognostic elements and implications for management.
Topics: Adrenergic Antagonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Convert | 2006 |
[ACE inhibitors or AT1 receptor antagonists?].
Topics: Age Factors; Aged; Angiotensin I; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme In | 1999 |
The antiarrhythmic potential of angiotensin II antagonism: experience with losartan.
Topics: Angiotensin Receptor Antagonists; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Death, Sudden, Cardi | 2000 |
7 trials available for losartan and Death, Sudden, Cardiac
Article | Year |
---|---|
Relationship of sudden cardiac death to new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy.
Topics: Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Confidence Intervals; Death, Sudden, C | 2013 |
QRS duration predicts sudden cardiac death in hypertensive patients undergoing intensive medical therapy: the LIFE study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Bundle-Branch Block; Death, Sudden, Card | 2009 |
QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Cause of Death; Death, Sudden, Cardiac; Elec | 2004 |
Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cause of Death; Death, Sudden, Cardiac; Female; Follo | 2005 |
Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Death, Sudden, Cardiac; Double-Blind Met | 2007 |
Effects of losartan and captopril on QT dispersion in elderly patients with heart failure. ELITE study group.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Captopril; Cardiotonic Agent | 1999 |
ACE inhibitors still the drug of choice for heart failure--and more.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Captopril; Death, Sudden, Cardiac | 1999 |
6 other studies available for losartan and Death, Sudden, Cardiac
Article | Year |
---|---|
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Comorbidit | 2003 |
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Topics: Aged; Antihypertensive Agents; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Comorbidity; Dea | 2003 |
LIFE: losartan versus atenolol.
Topics: Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Ther | 2003 |
LIFE: losartan versus atenolol.
Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Atenolol; Comorbidity; Death, Sudden, Cardiac; Diab | 2003 |
Angiotensin II-induced sudden arrhythmic death and electrical remodeling.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensinogen; Animals; Animals, Genetica | 2007 |
Experimental evidence to support ELITE.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Captopril; Death, | 1998 |